PEG-Capped Ceria–Zirconia Nanoparticles Improved Renal Fibrosis In Cellular and Animal Models of Fabry Disease-Reference-Cited by-同舟云学术

PEG-Capped Ceria–Zirconia Nanoparticles Improved Renal Fibrosis In Cellular and Animal Models of Fabry Disease

Published:2024-01-16 Issue:3 Volume:7 Page:2913-2928
ISSN:2574-0970
Container-title:ACS Applied Nano Materials
language:en
Short-container-title:ACS Appl. Nano Mater.

Author:

Kim Eun Kyung¹,Hong Sang-Eun²,Li Yi¹³,Yu Seong-Lan⁴,Choi Yun Seok¹,Kang Jaeku⁵^ORCID,Park Chang Gyo⁵,Lee Hoi Young⁵,Lee Sung-Ki⁴⁶,Lee Dong Chul⁷,Hwang Won Min¹,Yun Sung-Ro¹,Park Yohan¹,Park Moon Hyang⁸,Yoon Kuk Ro²,Yoon Se-Hee¹^ORCID

Affiliation:

1. Division of Nephrology and Department of Internal Medicine, Myunggok Medical Research Institute, College of Medicine, Konyang University, Daejeon 35365, Republic of Korea

2. Department of Chemistry, Hannam University, Daejeon 34054, Republic of Korea

3. ERSTEQ Inc, Daejeon 34013, Republic of Korea

4. Myunggok Medical Research Institute, College of Medicine, Konyang University, Daejeon 35365, Republic of Korea

5. Department of Pharmacology, College of Medicine, Konyang University, Daejeon 35365, Republic of Korea

6. Department of Obstetrics and Gynecology, College of Medicine, Konyang University, Daejeon 35365, Republic of Korea

7. Personalized Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34101, Republic of Korea

8. Department of Pathology, College of Medicine, Konyang University, Daejeon 35365, Republic of Korea

Funder

National Research Foundation of Korea

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsanm.3c05170

Reference41 articles.

1. Fibrosis: a key feature of Fabry disease with potential therapeutic implications

2. Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function Impairment

3. Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase β Therapy in Patients with Fabry Disease

4. Fabry disease: Mechanism and therapeutics strategies